AOD-9604

AOD-9604: Compound Overview
What is AOD-9604?
AOD-9604 (Advanced Obesity Drug-9604) is a modified form of the human growth hormone fragment 176-191. It consists of the C-terminal section of the HGH molecule, which researchers believe is responsible for the fat-burning effects of growth hormone, without influencing blood sugar or growth-promoting properties. It has been studied as a potential anti-obesity agent.
Mechanism of Action
AOD-9604 primarily stimulates lipolysis (the breakdown of fat) and inhibits lipogenesis (the formation of fat) in laboratory models. This effect is thought to be mediated by its mimicry of the natural metabolic actions of growth hormone, particularly through binding to adipose (fat) tissue.
Safety Profile
In preclinical and early human trials, AOD-9604 was generally well tolerated with minimal side effects. Notably, unlike full-length HGH, AOD-9604 does not appear to affect insulin sensitivity or IGF-1 levels, making it of interest in metabolic and obesity-related studies. However, its long-term effects are not well established, and it remains investigational.
Key Studies
Research published in Obesity Research & Clinical Practice explored AOD-9604’s effects on fat metabolism and found promising results in animal models.
Clinical trials in Australia and the U.S. evaluated its impact on weight loss, though it was not FDA-approved for therapeutic use.
Conclusion
AOD-9604 is an intriguing peptide for laboratories studying metabolic disorders, obesity, and fat metabolism. Its potential lipolytic benefits without the systemic effects of HGH make it a focused tool for understanding adipose regulation. All uses must remain within research contexts, and it is not intended for human consumption or therapeutic applications.